BioSpace News Archive

Entrada Therapeutics, Inc. today announced that Dipal Doshi, President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 11 newly-hired employees stock options to purchase an aggregate of 145,440 shares, and restricted stock units (RSUs) covering an aggregate of 56,330 shares, of BioCryst common stock.

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel”), an Israel-based dermatology company and Searchlight Pharma Inc. (“Searchlight”), a private Canadian specialty pharmaceutical company, today announced the signing of exclusive license agreements for TWYNEO and EPSOLAY for the Canadian market.

GenFleet Therapeutics published the latest results from the phase Ib/II study of GFH018 with toripalimab（anti-PD-1 antibody）at the 2023 American Society of Clinical Oncology Meeting in Chicago.

Kallyope, Inc. today announced the appointment of Franz Humer, Ph.D., a distinguished global industry leader in the life sciences, finance, and investment, as the new chair of its board of directors.

Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors.

Harvard University has invited Botanical Solution Inc. (BSI) CEO Gaston Salinas, (BSI), to speak at its upcoming seminar on Global Health, Biodiversity and Therapeutics, to be held Friday, June 9, 2023.

Zura Bio Limited, a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, announced the final closing of a private placement resulting in gross proceeds to Zura Bio of approximately $80 million.

TScan Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for TSC-200-A0201, a TCR-T targeting human papillomavirus 16 (HPV16).

XORTX Therapeutics Inc. is pleased to announce presentation of scientific data underpinning the recent Orphan Drug Designation (“ ODD ”) at the PKD Foundation – “PKD Connect” meeting being held June 22-24, 2023 in Denver, Colorado.